Is baricitinib an immunosuppressant?

Baricitinib (Baricitinib) is an immunosuppressant. It belongs to the drug class of Janus kinase inhibitors (JAK inhibitors for short). Baricitinib affects cell signaling pathways in the immune system by inhibiting the activity of Janus kinase, thereby reducing inflammation and immune responses.

The function of immunosuppressants is to suppress the activity of the immune system and reduce the degree of immune response. In some autoimmune diseases, the immune system becomes overactivated, leading to inflammation and tissue damage. By using immunosuppressants, the immune response can be reduced, thereby alleviating disease symptoms.

However, the use of immunosuppressants can also lead to a decrease in immune system resistance and increase the risk of infection. Therefore, when using baricitinib or other immunosuppressants, doctors will usually monitor the patient's immune function and provide appropriate preventive and monitoring measures to ensure the safety and effectiveness of the drug.

Baricitinib has been launched in China and is included in medical insurance. Patients can purchase it domestically. Due to different medical insurance reimbursement policies in different regions, the reimbursement ratio is also different. The price is about 1200~1600 yuan. For specific prices, please consult the local pharmacy or the medical insurance bureau. Baricitinib has both original and generic drugs abroad. The original drug is mainly Eli Lilly’s original drug, and its price is higher than in China. Generic drugs are mainly Bangladeshi generic drugs, and the price is around 450 yuan. The ingredients of original drugs and generic drugs are basically the same.